东西方肝癌的分析比较课件.ppt
- 【下载声明】
1. 本站全部试题类文档,若标题没写含答案,则无答案;标题注明含答案的文档,主观题也可能无答案。请谨慎下单,一旦售出,不予退换。
2. 本站全部PPT文档均不含视频和音频,PPT中出现的音频或视频标识(或文字)仅表示流程,实际无音频或视频文件。请谨慎下单,一旦售出,不予退换。
3. 本页资料《东西方肝癌的分析比较课件.ppt》由用户(晟晟文业)主动上传,其收益全归该用户。163文库仅提供信息存储空间,仅对该用户上传内容的表现方式做保护处理,对上传内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(点击联系客服),我们立即给予删除!
4. 请根据预览情况,自愿下载本文。本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
5. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007及以上版本和PDF阅读器,压缩文件请下载最新的WinRAR软件解压。
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 东西方 肝癌 分析 比较 课件
- 资源描述:
-
1、1Comparative Analyses of Hepatocellular Carcinoma between East and West Implication on the design of clinical trials 11th CSCO,Shanghai,2008Ann-Lii Cheng M.D.,Ph.D.Ann-Lii Cheng M.D.,Ph.D.Department of Oncology and Department of Internal Medicine,National Taiwan University Hospital;Taipei,Taiwan.Geo
2、graphic and ethnic factors become important in the era of molecular targeted therapy for cancersAsian(n=342)Non-Asian(n=1350)Proportion survivingTime(months)0.01.00.80.60.40.20246810 12 14 160246810 12 14 16GefitinibPlaceboImportance of Ethnicity for MTA the lessons of ISEL trialEGFR mutation rates
3、in each subgroupStudyCentreNo.of patientsAdenoCa(+BAC)(%)M(%)F(%)Smokers(%)n-smokers(%)Taiwan1NTUH624925612956Taiwan2VGH-T3767.452724469Korea3Seoul NU90219331326Japan4NCC Tokyo666153693568Japan5Aichi CCH596444704271HK6Chinese U7232China7Pek UMCH7648.632.334.8Italy8*U Chieti375106307251.Shih et al,IJ
4、C 20052.Chou et al,CCR 20053.Han et al,JCO 20054.Takano et al,JCO 2005*only AdenoCa5.Mitsudomi et al,JCO 20056.Lung et al,PAACR 20057.Mu et al,CCR 20058.Machetti et al,JCO 2005 Liver Cancer in the World Ferlay J et al.IARC Press,2001.Men(396,364)/Women(165,972)North America(%)2.07/2.61Central&South
5、America(%)2.09/4.33Africa(%)6.90/8.69Europe(%)8.21/10.45Asia(%)81.54/74.13Oceania(%)0.25/0.27Geographic differences in the results of clinical trials for advanced HCCSorafenibMedian:46.3 weeks(10.7 mo)(95%CI:40.9,57.9)Survival ProbabilityWeeksHazard ratio(S/P):0.69(95%CI:0.55,0.88)P=0.00058*PlaceboM
6、edian:34.4 weeks(7.9 mo)(95%CI:29.4,39.4)1.0000.750.500.250808162432404856647202742412051611086738120Patients at risk Sorafenib:027622417912678472572Placebo:299303Phase III SHARP TrialOverall survival(Intention-to-treat)Llovet J et al,N Engl J Med.2008 Jul 24;359(4):378-90 (7.9 mo)Comparison of Tx(-
7、)Control ArmsPt NoMedianOSPVTTNMStage IVOkudaStage IIIECOGIII/IVSpain10217M23.5%54.9%0%*0%*HK1063M60.0%90.6%14%13%*Spanish trials excluded“End-stage disease”Llovet JM,Hepatology 1999;29:62-7Yeung YP,Am J Gastroenterol 2005;100:1995-2004EAST VS WESTRandomized trials-octreotide vs placebo Study Schema
8、 of SHARP and AP StudiesSorafenib400 mg bidPlaceboEligibility Advanced HCCECOG 0-2Child-Pugh ANo prior systemic therapyStratification Macroscopic vascular invasion(portal vein)and/or extrahepatic spreadECOG PSGeographic areaRANDOMIZEPhase III SHARP and Asia-Pacific Overall SurvivalSorafenibMedian:10
9、.7 months(95%CI:40.9,57.9)Survival ProbabilityMonthsHazard ratio(sor/pla):0.69(95%CI:0.55,0.87)P=0.00058*PlaceboMedian:7.9 months(95%CI:29.4,39.4)1.0000.750.500.25020246810 12 14 16 18Survival ProbabilitySorafenibMedian:6.5 months(95%CI:5.6-7.6)PlaceboMedian:4.2 months(95%CI:3.7-5.5)HR(S/P):0.68 95%
10、CI:0.50-0.93P=0.0140.250.500.751.0000Months248 10 12 14 1620 22618Llovet JM,et al.N Engl J Med 2008:359:378-90 Cheng AL,et al.ASCO 2008,Abstract 4509.SHARPSHARPAsia-PacificAsia-PacificAsia-Pacific Liver Cancer Study vs SHARP:Baseline Patient CharacteristicsAsia-Pacific(N=226)SHARP1(N=602)Median age(
11、range),years51(23-86)67(21-89)Hepatitis virus status(HBV/HCV),%73/818/28Sex(Male),%8587ECOG PS(0/1/2),%26/69/554/38/8Macroscopic vascular invasion,%3538Extrahepatic spread,%6951BCLC Stage(B/C),%4/9617/82No.of tumor sites,%11144 23531 32012 43513Sites of disease,%Lung5021Lymph node32261 Llovet J,et a
12、l.N Engl J Med 2008:359:378-90.Llovet JM et al.Lancet.2003;362:1907-1917.End StageAdvanced StageIntermediate StageEarly StageSurgical TreatmentsLocal AblationNew AgentsTACEHCC(30%)Potentially curative treatments5-yr survival:50-70%(50-60%)Randomized trialsmedian survival if untreated:6-16 mo(10%)BSC
13、 survival 2 or Child CPVT(-)PVT(+)Single2 or 3,3 cm4,3 cmICG good*ICG bad*ResectionAblation,Transplan-tationTACEMain PV(-),extra-hepatic spread(-)Main PV(+)or extra-hepatic spread(+)TACEBSCNew agentsBSCBil.2 mg/dlBil.2 mg/dlBil.2 mg/dlBil.2 mg/dlEarly stage(single or 3 nodules 3 cm,PS 0)Intermediate
14、 stage(multi-nodular,PS 0)Advanced stage(portal invasion,N1,M1,PS 1-2Terminal stage(PS 2,Child C)NTUH practiceBCLC guidelineResectionAblation,Transplan-tationTACENew agentsBSCSingle,PH(-)Multiple,PH(+)Makuuchi M.et al,Hepatology Research 2007Japan GuidelineEmbolization hepatic arterial infusion chem
15、otherapyGeographic differences in the etiology of HCC implication in the development of MTAsEtiology of HCC Distinct Geographic Distribution Risk FactorsHepatitis B virusHepatitis C virusAlcoholTobaccoOral contraceptivesAflatoxinOther and emerging risk factors/cofactors Estimate Range 22 4-58 60 127
16、2 45 857 12 014 -1050 Limited exposure 5 -Estimate Range 20 18-44 63 4894 20 1533 40 951 -Limited exposure -Estimate Range 60 4090 20 956 -1141 22 -8 -Important exposure 5 -Bosch FX et al.Gastroenterology 2004;127:S5-16.Europe and United States(%)Japan(%)Asia and Africa(%)Is HBV-related HCC a more a
17、ggressive tumor?Is HBV-related HCC associated with molecular changes which affect molecular therapy?HBV-related HCCHCC East vs WestLong-term results after surgical treatment were similar in West and East when clinicopatnologic factors were accounted for.Pawlik TM et al Liver Transplantation 2004;10(
18、suppl 1)74-80Taeck D et al Liver Transplantation 2004;10(suppl 1)58-63 HBV vs.HCV HCCItalian Liver Cancer groupSurvival in patients with advanced HCC.HBV-HCC patients had a lower survival than HCV-HCC patients(p=0.025)Patients with HBV-HCC tended to have poor prognosis;Cantarini MC et al:Am J Gastro
19、enterol 2006;101:91-8.and the difference became statistically significant among patients with advanced HCCHBV vs.HCV HCC in NTUHSurvival for patients with advanced ds.927 patients receiving supportive care or chemotherapy.EtiologyMedian survival(M)1 year(%)3 year(%)5 year(%)10 year(%)HBV2.5 12.43.40
展开阅读全文